Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21321887 | 1.00 | SMN1; SMN2 (0.35) | SMN1; SMN2CHRNA7HSD11B1ALDH1A1KDM4E | |
| SCHEMBL26744681 | 1.00 | SMN1; SMN2 (0.35) | SMN1; SMN2CHRNA7HSD11B1ALDH1A1KDM4E | |
| SCHEMBL2560152 | 1.00 | SMN1; SMN2 (0.35) | SMN1; SMN2CHRNA7HSD11B1ALDH1A1KDM4E | |
| SCHEMBL26744647 | 1.00 | SMN1; SMN2 (0.35) | SMN1; SMN2CHRNA7HSD11B1ALDH1A1KDM4E | |
| SCHEMBL27020232 | 0.91 | PAOX (0.33) | SMN1; SMN2CHRNA7HSD11B1ALDH1A1 | |
| SCHEMBL18975210 | 0.89 | HSD11B1 (0.31) | SMN1; SMN2CHRNA7HSD11B1 | |
| SCHEMBL28374092 | 0.86 | — | — | |
| SCHEMBL13563118 | 0.84 | MEN1 (0.40) | SMN1; SMN2HSD11B1ALDH1A1KDM4EGAA | |
| SCHEMBL16356924 | 0.84 | HSD17B10 (0.41) | SMN1; SMN2HSD11B1ALDH1A1KDM4EGAA | |
| SCHEMBL26615410 | 0.84 | HSD17B10 (0.41) | SMN1; SMN2HSD11B1ALDH1A1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | SMN1; SMN2 3725/4885CHRNA7 674/4885HSD11B1 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.